Interstitial lung disease (ILD) encompasses a large and diverse group of pathological
conditions that share similar clinical, radiological and pathological manifestations, despite …

Pulmonary fibrosis is a chronic lung disease characterized by excessive accumulation of
extracellular matrix (ECM) and remodeling of the lung architecture. Idiopathic pulmonary …

Pulmonary fibrosis (PF) is a major public health problem with limited therapeutic options.
There is a clear need to identify novel mediators of PF to develop effective therapeutics …

Pulmonary fibrosis (PF) is the devastating consequence of various inflammatory diseases of
the lung. PF leads to a reduction of lung function, respiratory failure, and death. Several …

Dysregulated amphiregulin (AR) expression and EGR receptor (EGFR) activation have been
described in animal models of pulmonary fibrosis and in patients with idiopathic pulmonary …

Repetitive pulmonary injury causes fibrosis and inflammation that underlies chronic lung
diseases such as idiopathic pulmonary fibrosis (IPF). Interleukin 11 (IL11) is important for …

Carbon nanotubes (CNTs) are newly developed materials with unique properties and a
range of industrial and commercial applications. A rapid expansion in the production of CNT …

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and devastating disorder. It is
characterized by alveolar epithelial cell injury and activation, infiltration of inflammatory cells …

Current hypotheses suggest that aberrant wound healing has a critical role in the
pathogenesis of idiopathic pulmonary fibrosis (IPF). In these hypotheses, continuous TGF-β1 …

Background Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease with no known
effective therapy. It is often assumed, but has not been objectively evaluated, that pulmonary …